To the Editor The development of novel and effective strategies aimed at modifying the course of Alzheimer disease (AD) is urgently needed. In a recent double-blind randomized clinical trial, Howard and colleagues1 reported that minocycline, a broad-spectrum antibiotic, failed to provide clinical benefits (as assessed by changes in scores of the Mini-Mental State Examination and the Bristol Activities of Daily Living scale) in a cohort of persons with a diagnosis of early AD. The rationale for the investigation of minocycline stems from preclinical evidence supporting the notion that the drug targets critical determinants of AD-like β-amyloid, hyperphosphorylated tau, and microglia activation and neuroinflammation.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Granzotto A, Sensi SL. Minocycline—A Lesson From a Failure. JAMA Neurol. Published online May 18, 2020. doi:10.1001/jamaneurol.2020.1154
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: